Stockscreener 앱 받기
3.16
10.73%
-0.38
시간 외 거래:
3.17
0.010
+0.32%
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.
LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace
Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Simply Wall St
Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire
Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire
FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace
FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com
After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph
11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex
Lantern Pharma secures three new FDA rare disease tags - Investing.com
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace
Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch
Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance
NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma - OncLive
11 Penny Stocks That Will Make You A Millionaire - Insider Monkey
LTRN (Lantern Pharma) EPS (Basic) : $-1.65 (TTM As of Jun. 2024) - GuruFocus.com
The Targeted Pulse: Apalutamide Provides a Faster, Deeper PSA Response vs Enzalutamide, Vorasidenib Receives Approval in Glioma, and More - Targeted Oncology
Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update - Defense World
LTRN (Lantern Pharma) 50-Day SMA : $4.42 (As of Aug. 17, 2024) - GuruFocus.com
LTRN (Lantern Pharma) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Q3 2024 Earnings Forecast for Lantern Pharma Inc. (NASDAQ:LTRN) Issued By Zacks Small Cap - Defense World
LTRN: Second Quarter Results - Yahoo Finance
The Targeted Pulse: The Practice-Changing Approval of Afami-cel for Advanced Synovial Sarcoma, Buprenorphine Offers Pain Relief for Bone Marrow Transplant, and More - Targeted Oncology
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript - Seeking Alpha
LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 - MSN
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 - Business Wire
Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World
LTRN: Harmonic Clinical Update - Zacks Small Cap Research
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort - Chronicle-Tribune
3.66%
1.11%
자본화:
|
볼륨(24시간):